Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

P0rNsTaR Jun. 3 at 7:01 PM

$ABVX I smell an announcement soon! $LLY $PFE $JNJ

0 · Reply

P0rNsTaR Jun. 3 at 6:17 PM

$ABVX someone wanted to buy them cheap. Wait for this stock to hit $200 once the deal is announced. Then $300 once the drug is approved! So which of these companies is going to buy Abivax $LLY or $JNJ $MRNA

0 · Reply

P0rNsTaR Jun. 3 at 5:20 PM

$ABVX a drug 40% effective. Best in class. Better than injectables. $JNJ $LLY $ABBV https://www.biopharmadive.com/news/abivax-obefazimod-abtect-ulcerative-colitis-results-cancer/821685/

0 · Reply

MartinGreymarkets Jun. 3 at 3:23 PM

6/5 $JNJ 235c @.13

1 · Reply

P0rNsTaR Jun. 3 at 2:43 PM

$ABVX should be back to $130 after this manipulation and overreaction. 60% upside. $LLY $JNJ

1 · Reply

MissMoon Jun. 3 at 1:46 PM

$JNJ $LASE $SPY

0 · Reply

MissMoon Jun. 3 at 1:43 PM

$LASE $SPY DOW picked this. Contracts will be flying in! $JNJ ordered them last week. Legit 120%

0 · Reply

CapitalMonk Jun. 3 at 1:05 PM

$JNJ Price: $222.89 (-0.28%) Trend: Bullish Market Bias (7D): Sideways ⚖️ Expected Range: ±0.73% RSI: 49.9 | Momentum: Moderate Volume: -26.0% vs avg Volatility: 1.16% Support: $219.11 | Resistance: $234.15 Data and analytics sourced from Given Analytics educational research: https://www.givenanalytics.com/

0 · Reply

focafoca99 Jun. 3 at 8:59 AM

$JNJ detailed new biomarker data showing nipocalimab reduces autoantibodies in Sjögren's disease, to be presented at the EULAR Congress. https://www.rapidticker.com/news/jnj-johnson-johnson-presents-new-data-58d1b0

0 · Reply

focafoca99 Jun. 3 at 8:55 AM

$JNJ posted late-breaking Phase 2 results showing nipocalimab significantly reduced SLE disease activity. https://www.rapidticker.com/news/jnj-johnson-johnson-late-breaking-results-8a92d2

0 · Reply

Johnson & Johnson presents exploratory analyses from DAHLIAS study

2026-06-03T09:31:04.000Z - 15 hours ago

Johnson & Johnson announces nipocalimab met primary endpoint in JASMINE study

Jun 3, 2026, 12:04 AM EDT - 21 hours ago

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

SLE

Jun 3, 2026, 12:03 AM EDT - 21 hours ago

Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

Jun 2, 2026, 6:24 PM EDT - 1 day ago

Jim Cramer says look to buy these 5 stocks outside the AI trade for diversification

JPM KMB MCD YUM

2026-05-31T21:41:49.000Z - 3 days ago

Johnson & Johnson announces Phase 3 Proteus study met primary endpoints

2026-05-31T21:40:07.000Z - 3 days ago

Johnson & Johnson announces results from Phase 1b/2 OrigAMI-4 study

May 31, 2026, 8:39 AM EDT - 3 days ago

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm

May 31, 2026, 8:29 AM EDT - 3 days ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited

May 31, 2026, 8:27 AM EDT - 3 days ago

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm

May 31, 2026, 8:01 AM EDT - 3 days ago

J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study

May 29, 2026, 2:00 PM EDT - 5 days ago

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

2026-05-29T12:49:22.000Z - 5 days ago

Johnson & Johnson reports new data from Phase 3 MajesTEC-9 study

May 29, 2026, 8:18 AM EDT - 5 days ago

New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma

May 28, 2026, 7:10 PM EDT - 6 days ago

FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage

May 28, 2026, 5:30 AM EDT - 6 days ago

J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?

May 27, 2026, 4:22 PM EDT - 7 days ago

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

May 27, 2026, 11:00 AM EDT - 7 days ago

Johnson & Johnson Transcript: Bernstein 42nd Annual Strategic Decisions Conference

May 21, 2026, 7:00 AM EDT - 13 days ago

Johnson & Johnson Advances Creation of Global Intelligent OR Network in collaboration with Department of Health - Abu Dhabi

May 21, 2026, 4:31 AM EDT - 13 days ago

Johnson & Johnson says nipocalimab approved in China

May 19, 2026, 11:30 AM EDT - 15 days ago

Johnson & Johnson Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 19, 2026, 9:00 AM EDT - 15 days ago

Portal Innovations and New Brunswick Development Corporation Collaborate with Johnson & Johnson to Name the Johnson & Johnson Exchange at the New Jersey Innovation Hub in HELIX, Advancing the State's Life Sciences Leadership

May 14, 2026, 4:01 PM EDT - 20 days ago

Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation

STGW

May 12, 2026, 2:20 PM EDT - 22 days ago

Johnson & Johnson Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 7:45 AM EDT - 22 days ago

Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter

May 11, 2026, 4:34 PM EDT - 23 days ago

Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

May 11, 2026, 8:00 AM EDT - 23 days ago

Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP

May 7, 2026, 11:34 AM EDT - 27 days ago

This Dividend Pro Likes Banks, Semi-Equipment Stocks, Altria, and J&J

May 7, 2026, 8:00 AM EDT - 27 days ago

Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission

May 5, 2026, 9:15 AM EDT - 4 weeks ago

CVS to drop J&J's Stelara from its main formularies

CVS

May 5, 2026, 8:05 AM EDT - 4 weeks ago

Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease

$Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease$

May 5, 2026, 8:05 AM EDT - 4 weeks ago

Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease

May 5, 2026, 7:00 AM EDT - 4 weeks ago

Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System

May 4, 2026, 8:00 AM EDT - 4 weeks ago

CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis

May 2, 2026, 4:00 AM EDT - 4 weeks ago

J&J's $1.7 Billion Drug Ushers in Age of Psychedelic Medicine

Apr 30, 2026, 8:02 AM EDT - 4 weeks ago

Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations

Apr 28, 2026, 11:10 AM EDT - 5 weeks ago

Why These 3 Forever Stocks Belong on Your Watchlist

WMT XOM

Apr 27, 2026, 4:33 PM EDT - 5 weeks ago

Johnson & Johnson to Participate in the Bernstein's 42nd Annual Strategic Decisions Conference

Apr 27, 2026, 11:03 AM EDT - 5 weeks ago

J&J sees AI halving the time to generate drug development leads

Apr 27, 2026, 8:03 AM EDT - 5 weeks ago

FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)

Apr 24, 2026, 4:30 PM EDT - 5 weeks ago

Johnson & Johnson to launch on TrumpRx with four of its prescription drugs, CBS News reports

Apr 23, 2026, 6:44 PM EDT - 5 weeks ago

Cramer says look to these 4 stocks to go with your high-flying tech names

CAH CVS UNH

Apr 23, 2026, 10:00 AM EDT - 5 weeks ago

Johnson & Johnson Transcript: AGM 2026

Apr 22, 2026, 8:05 AM EDT - 6 weeks ago

IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)

Apr 22, 2026, 4:00 AM EDT - 6 weeks ago

Johnson & Johnson Announces CE Mark Approval for the New ETHICON™ 4000 Stapler

Apr 21, 2026, 4:22 PM EDT - 6 weeks ago

Johnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Apr 21, 2026, 7:45 AM EDT - 6 weeks ago

Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026

Apr 17, 2026, 10:36 PM EDT - 6 weeks ago

US judge rejects Bayer bid to block Johnson & Johnson prostate cancer drug claims

Apr 17, 2026, 7:00 PM EDT - 6 weeks ago

U.S. judge rejects Bayer's bid to block Johnson & Johnson prostate cancer drug claims

Apr 15, 2026, 4:11 PM EDT - 7 weeks ago

Johnson & Johnson to Participate in the Bank of America 2026 Healthcare Conference

Apr 14, 2026, 10:51 AM EDT - 7 weeks ago

Johnson & Johnson CFO on the company's robotic surgical system

Apr 14, 2026, 10:30 AM EDT - 7 weeks ago

Tuesday's Morning Movers: ORCL & BE Extend Partnership, KMX & JNJ Earnings

ORCL BE KMX

Apr 14, 2026, 8:30 AM EDT - 7 weeks ago

Johnson & Johnson Earnings Call Transcript: Q1 2026

Apr 14, 2026, 8:30 AM EDT - 7 weeks ago

Johnson & Johnson Earnings release: Q1 2026

Apr 14, 2026, 8:30 AM EDT - 7 weeks ago

Johnson & Johnson Slides: Q1 2026

Apr 14, 2026, 8:30 AM EDT - 7 weeks ago

Johnson & Johnson Quarterly report: Q1 2026

Apr 14, 2026, 6:55 AM EDT - 7 weeks ago

J&J raises guidance for 2026 on strong start to the year

Apr 14, 2026, 6:25 AM EDT - 7 weeks ago

J&J's first-quarter profit beats estimates even as Stelara sales disappoint

Apr 14, 2026, 6:21 AM EDT - 7 weeks ago

Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%

Apr 14, 2026, 6:20 AM EDT - 7 weeks ago

Johnson & Johnson reports Q1 2026 results, raises 2026 outlook

Apr 14, 2026, 6:20 AM EDT - 7 weeks ago

J&J's First-Quarter Sales Grow on Cancer-Drug Strength

Apr 12, 2026, 2:00 PM EDT - 7 weeks ago

Goldman Sachs, Bank of America, JP Morgan, Netflix, J&J, Producer Prices, and More to Watch This Week

NFLX BAC GS JPM

Apr 10, 2026, 8:00 AM EDT - 7 weeks ago

Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision

P0rNsTaR Jun. 3 at 7:01 PM

$ABVX I smell an announcement soon! $LLY $PFE $JNJ

0 · Reply

P0rNsTaR Jun. 3 at 6:17 PM

0 · Reply

P0rNsTaR Jun. 3 at 5:20 PM

$ABVX a drug 40% effective. Best in class. Better than injectables. $JNJ $LLY $ABBV https://www.biopharmadive.com/news/abivax-obefazimod-abtect-ulcerative-colitis-results-cancer/821685/

0 · Reply

MartinGreymarkets Jun. 3 at 3:23 PM

6/5 $JNJ 235c @.13

1 · Reply

P0rNsTaR Jun. 3 at 2:43 PM

$ABVX should be back to $130 after this manipulation and overreaction. 60% upside. $LLY $JNJ

1 · Reply

MissMoon Jun. 3 at 1:46 PM

$JNJ $LASE $SPY

0 · Reply

MissMoon Jun. 3 at 1:43 PM

$LASE $SPY DOW picked this. Contracts will be flying in! $JNJ ordered them last week. Legit 120%

0 · Reply

CapitalMonk Jun. 3 at 1:05 PM

0 · Reply

focafoca99 Jun. 3 at 8:59 AM

0 · Reply

focafoca99 Jun. 3 at 8:55 AM

$JNJ posted late-breaking Phase 2 results showing nipocalimab significantly reduced SLE disease activity. https://www.rapidticker.com/news/jnj-johnson-johnson-late-breaking-results-8a92d2

0 · Reply

P0rNsTaR Jun. 3 at 3:28 AM

$ABVX that was an orchestrated drop in stock price to get shares for cheap. Easy ride back up to $130. $LLY $JNJ

0 · Reply

InnTheeMoney Jun. 3 at 3:09 AM

$JNJ $SPY $META $QUBT 230

0 · Reply

InnTheeMoney Jun. 3 at 3:09 AM

$JNJ open at 230 big news incoming

0 · Reply

WallStreetPimp Jun. 2 at 8:23 PM

$JNJ https://laserphotonics.com/news/press-releases/laser-photonics-expands-into-precision-medical-device-manufacturing-with-custom-laser-drilling-system-order-from-johnson-johnson/?srsltid=AfmBOoqKR5msOAMqW6bJu7qPVUs-Us9lFy2DuZY8kM-40npwd7xyZQtj $LASE

0 · Reply

Suite510 Jun. 2 at 8:12 PM

$BAYRY $JNJ $KVUE Get ready JNJ your up next with 67,000 lawsuits for Talc Cancer Deaths the largest MDL in the USA! Clock is ticking nowhere to hide 🙈 “Bayer Shares Fall on Renewed Uncertainty Over $7 Billion U.S. Settlement”

1 · Reply

Randomizer123 Jun. 2 at 4:02 PM

$LEGN If any early-stage company claimed thry got 100% ORR in lymphoma with their Invivo CAR-T, the experts and analysts will look at their claim with a dose of scepticism. But If this claim comes from Legend Biotech, the inventor of Carvykti, the highest selling ex vivo CAR-T with functional cure for MM with >5 yr data, you better take a bow and take them seriously. $JNJ ‘will’ win the bidding war at all cost, be it a specific In Vivo CAR-T program for lymphoma or multiple Programs or total BO.

0 · Reply

ElliottwaveForecast Jun. 2 at 4:00 PM

After breaking out, what's the next price target for $JNJ amid the current pullback? 📈 Find out here: https://elliottwave-forecast.com/stock-market/jnj-elliott-wave-signals-rally-toward-259/ #Stocks #Trading #JNJ

0 · Reply

OptionSamurai Jun. 2 at 2:56 PM

$JNJ appears in our scan that looks for calls that will explode if the stock goes to analyst target. ✔ Analysts rating is BUY ✔ The analyst target price is 17.2% away ✔ IV Percentile is 76.2% Call 230.0, 21-Aug-26 has: 💀 Max loss of 3.5% compared to holding shares ⚖ Breakeven is 6.6% away 📈 If the stock hits the target, the call will profit 304% 🔥 See more results & create your own scan here: https://bit.ly/3lR1xIP

0 · Reply

Night_Owl_Biotech Jun. 2 at 2:27 PM

$URGN This is not investment advice because we have no idea what will happen to UroGen. We'd only remind investors $ITCI announced they settled a similar patent dispute allowing Sandoz to market a generic Caplyta by 2040. ITCI announced the settlement 2 or 3 days before they announced they were being acquired by $JNJ Again, this is not investment advice. $TEVA can market a generic Jelmyto in 2030 which (most likely) limits Jelmyto's M&A valuation. Of course Zusduri is anticipated to outsell Jelmyto 7 or so to 1. Good luck

0 · Reply

OnlyFibs Jun. 2 at 3:36 AM

$JNJ trading ~$223.51, showing aggressive institutional positioning as shown in "image_ab5278.png" with significant call blocks targeting the $230–$250 range through August. 📈 Setup: Smart money is betting on a summer recovery, with heavy block buying in the $230 calls (07/17) and $250 calls (08/21), indicating institutional confidence in the oncology pipeline. 🐂 Bull Trigger: A clean daily close above $230.00 confirms the institutional breakout, setting the stage for a push toward $240.00 and beyond. 🐻 Bear Level: A failure to hold $220.00 support invalidates the bullish flow and risks a deeper retest of the $215.00 zone. 📊 Trend: BULLISH — Unusual option activity shows clear accumulation at these levels, betting on a reversal driven by pipeline execution. #jnj #optionsflow #hovdid

0 · Reply

ROCKSTAR_X Jun. 1 at 6:53 PM

$JNJ 225. Eod or eow!?

0 · Reply

pilobious Jun. 1 at 4:55 PM

$JNJ very weak the last few days. Looking for news.

0 · Reply

Market Cap	542.42B
Revenue (ttm)	94.19B
Net Income (ttm)	26.80B
EPS (ttm)	N/A
PE Ratio	21.00
Forward PE	19.47
Profit Margin	28.46%
Debt to Equity Ratio	0.46

Volume	6,507,200
Avg Vol	7,573,760
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	14%
Beta	0.27
Analysts	Strong Sell
Price Target	$260.46